News|Videos|July 29, 2026

Oncology PulsePoint: How Updated Immunotherapy Guidelines are Changing Renal Cell Carcinoma Care

Author(s)Angie Maynard, PharmD, MS, BCOP, Ryu Kariyawasam-Chavez, Content Associate

Angie Maynard, PharmD, MS, BCOP, discusses RCC immunotherapy guidelines, treatment selection, toxicity management, and pharmacists’ clinical role.

In an interview with Pharmacy Times, Angie Maynard, PharmD, MS, BCOP, discussed key updates to the Society for Immunotherapy of Cancer clinical practice guidelines for immunotherapy in renal cell carcinoma, with a primary focus on clear cell renal cell carcinoma.

Related to this article

October 28th, 2026

Oncology PulsePoint: How NCCN Breast Cancer Updates Are Changing Testing and Treatment

In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.

Molecular model of Pembrolizumab | Image Credit: © Dr_Microbe - stock.adobe.com

October 28th, 2026

Chemotherapy-Free Pembrolizumab Extends PFS in First-Line dMMR Endometrial Cancer

Phase 3 data show pembrolizumab beats chemotherapy, offering durable first-line control with fewer severe toxicities and chemo-free potential.

Professional female pharmacist in white coat explaining prescription medication to a senior woman patient at pharmacy counter | Image Credit: © ideas - stock.adobe.com

October 28th, 2026

The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment

Specialty pharmacy liaisons improve breast cancer care by easing access barriers, managing side effects, boosting adherence, and navigating new therapies and policies.

October 27th, 2026

Cancer Pain Relief Starts With a Constipation Plan

Pharmacists can support effective cancer pain treatment by starting constipation prevention with opioid therapy and reassessing bowel function before symptoms become a barrier to care.

October 27th, 2026

Ribociclib Shows Overall Survival Benefit at 6 Years in NATALEE Breast Cancer Trial

Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.

IgG4-Related Kidney Disease: Why It’s Missed and How to Treat It

October 27th, 2026

Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show

October 26th, 2026

FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer

The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.

October 26th, 2026

Protecting Bone Health During Breast Cancer Endocrine Therapy

Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.